CPMV Mosaic ImmunoEngineering Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 836564 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY0.8%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-2,254.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets238,930.6%
Debt / equity—
Current ratio0.00x
Interest coverage-60.40x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-2,078.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $63,981 | $183,867 | $435,449 | $1.05M | $1.46M |
| SG&A expense | $552,138 | $695,788 | $964,319 | $1.58M | $2.05M |
| Operating income | -$616,119 | -$879,655 | -$1.40M | -$2.63M | -$3.50M |
| Interest expense | $10,001 | $6,954 | $0 | — | — |
| Pretax income | -$685,446 | -$919,583 | -$1.01M | -$2.38M | -$3.68M |
| Income tax | $2,400 | $2,400 | $2,400 | $2,400 | $2,400 |
| Net income | -$687,846 | -$921,983 | -$1.01M | -$2.38M | -$3.68M |
| EPS (basic) | -0.10 | -0.13 | -0.14 | -0.33 | -0.55 |
| EPS (diluted) | -0.10 | -0.13 | -0.14 | -0.33 | -0.55 |
| Weighted avg. shares (diluted) | — | 7.24M | 7.24M | 7.24M | 6.71M |
| Banking | |||||
| Noninterest expense | — | — | $73,333 | $69,738 | $30,121 |
| Balance sheet | |||||
| Cash & equivalents | $3,622 | $115,019 | $156,178 | $220,645 | $226,142 |
| Current assets | $19,882 | $141,611 | $179,533 | $261,277 | $269,494 |
| Total assets | $19,882 | $141,611 | $179,533 | $261,277 | $269,494 |
| Current liabilities | $6.03M | $5.54M | $4.73M | $3.92M | $2.33M |
| Total liabilities | $7.50M | $6.93M | $6.05M | $5.15M | $3.07M |
| Shareholders' equity | -$7.48M | -$6.79M | -$5.87M | -$4.88M | -$2.80M |
| Shares outstanding | 7.24M | 7.24M | 7.24M | 7.24M | 7.24M |
| Cash flow statement | |||||
| Operating cash flow | -$111,397 | -$241,159 | -$497,467 | -$690,129 | -$679,236 |
| Investing cash flow | — | $0 | $433,000 | $343,000 | $27,637 |
| Financing cash flow | $0 | $200,000 | $0 | $341,632 | $525,003 |
| Stock-based compensation | $0 | $4,867 | $21,935 | $295,123 | $1.31M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.